Zilebesiran

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HypertensionCardiovascular Disease

566 competitors in Hypertension

#DrugCompanyPhaseTrials

1

Zilebesiran

Alnylam Pharmaceuticals

Phase 3

32

Edarbi

Takeda

Preclinical

103

Benicar

Novartis

Preclinical

74

Apresoline

Novartis

Preclinical

75

Zebeta

Teva

Preclinical

66

Edarbi

Takeda

Preclinical

47

Aceon

Institut de Recherches Internationales Servier

Preclinical

58

Winrevair

Merck & Co.

Preclinical

—9

Alphagan

AbbVie

Preclinical

—10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1Show 18 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hypertension3 trials

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Completed·Alnylam Pharmaceuticals·Phase 2·NCT06272487·375 enrolled

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Completed·Alnylam Pharmaceuticals·Phase 1/2·NCT06423352·36 enrolled

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Completed·Alnylam Pharmaceuticals·Phase 2·NCT05103332·663 enrolled

High Risk Cardiovascular Disease1 trial

ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Recruiting·Alnylam Pharmaceuticals·Phase 3·NCT07181109·11,000 enrolled

Details

Drug Info

Related News